Drug Information

Drug (ID: DG01731) and It's Reported Resistant Information
Name
Bevacizumab/Gefitinib
Synonyms
Bevacizumab/Gefitinib
    Click to Show/Hide
Target . NOUNIPROTAC [1]
Type(s) of Resistant Mechanism of This Drug
  ADTT: Aberration of the Drug's Therapeutic Target
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Click to Show/Hide the Resistance Disease of This Class
Lung cancer [ICD-11: 2C25]
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: Epidermal growth factor receptor (EGFR) [1]
Molecule Alteration Complex-indel
p.H773_V774delinsLM (c.2317_2322delinsCTTATG)
 Molecule Info 
Sensitive Disease Lung adenocarcinoma [ICD-11: 2C25.0]
 Disease Info 
Experimental Note Identified from the Human Clinical Data
References
Ref 1 Case Report: Osimertinib achieved remarkable and sustained disease control in an advanced non-small-cell lung cancer harboring EGFR H773L/V774M mutation complexLung Cancer. 2018 Jul;121:1-4. doi: 10.1016/j.lungcan.2018.04.006. Epub 2018 Apr 5.
insuranceusa.com
visits since 2022

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.